Good Times Restaurants Inc. (NASDAQ:GTIM) shares increased 2.57% in last trading session and ended the day at $3.99. GTIM Gross Margin is 26.80% and its has a return on assets of -4.10%. Good Times Restaurants Inc. (NASDAQ:GTIM) quarterly performance is -10.74%.
Good Times Restaurants Inc. (NASDAQ:GTIM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday,AnalystRatings.Net reports.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) ended the last trading day at $6.27. Company weekly volatility is calculated as 5.96% and price to cash ratio as 4.92. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) showed a weekly performance of -4.71%.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) has named Manmeet Soni as its chief financial officer and treasurer, effective Mar. 21. Soni will report to Paris Panayiotopoulos, president and CEO of ARIAD.
On 18 March, IMAX Corporation (NYSE:IMAX) shares decreased -1.46% and was closed at $31.63. IMAX EPS growth in last 5 year was -12.50%. IMAX Corporation (NYSE:IMAX) year to date (YTD) performance is -11.00%.
On 16 March, IMAX Corporation (NYSE:IMAX) launched an ambitious corporate social responsibility initiative, “Big Picture,” as an extension of its core mission to educate, entertain and inspire movie audiences globally. The wide-ranging campaign will leverage the power of film to promote awareness of and appreciation for the “big picture,” the understanding that the actions we take in our daily lives can significantly impact the future of the planet.
PTC Therapeutics, Inc. (NASDAQ:PTCT) shares increased 7.82% in last trading session and ended the day at $5.93. PTCT has a return on assets of -51.00%. PTC Therapeutics, Inc. (NASDAQ:PTCT) quarterly performance is -82.58%.
On 14 March, PTC Therapeutics, Inc. (NASDAQ:PTCT) announced that the company intends to submit the results of the recently completed Phase 3 ACT DMD study for review by Health Canada as part of the New Drug Submission (NDS) for Translarna™ (ataluren) to treat nonsense mutation Duchenne muscular dystrophy (nmDMD).
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) caters to the Healthcare space. It has a net profit margin of -50.40% and weekly performance is 3.49%. On the last day of trading company shares ended up at $7.12. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) distance from 50-day simple moving average (SMA50) is 4.01%.
On 14 March, Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced it has signed a definitive agreement to acquire all of Bioject Medical Technologies Inc.’s assets including pioneering needle-free jet injection technology, devices, and intellectual property. Inovio will pay Bioject $5.5 million in cash and stock.
Leave a Reply